eflapegrastim
Generic: eflapegrastim·Brand: Rolvedon
eflapegrastim: developed by 1 company · 1 clinical trial tracked.
eflapegrastim evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect eflapegrastim to SPPI; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could eflapegrastim → SPPI affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SPECTRUM PHARMACEUTICALS INC (SPPI) | Phase 2 |
Clinical Trials (1)
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Interventionalopen40 targetStarted 2021-05Completion 2027-105 sites · United StatesSpectrum Pharmaceuticals, Inc
Frequently asked questions
Who is developing eflapegrastim?
eflapegrastim is being developed by SPECTRUM PHARMACEUTICALS INC.
How many clinical trials involve eflapegrastim?
BioSniper tracks 1 clinical trial involving eflapegrastim.